Clinical Trial Update: A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating anti-PD1 antibody-activated tumor-infiltrating lymphocytes in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• anti-PD1 antibody-activated TILs (PD-1 antibody-activated tumor-infiltrating lymphocytes)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN